Photo by nci from unsplash
Multigene assay is recommended currently for prognostic stratification of the clinically indeterminate group of breast cancer (BC) patients defined as lymph node (LN)‐negative, oestrogen receptor (ER)‐positive, HER2‐negative (LN−/ER+/HER2−) to determine… Click to show full abstract
Multigene assay is recommended currently for prognostic stratification of the clinically indeterminate group of breast cancer (BC) patients defined as lymph node (LN)‐negative, oestrogen receptor (ER)‐positive, HER2‐negative (LN−/ER+/HER2−) to determine the use of chemotherapy. However, this cohort, comprising approximately 40% of BC, is not a homogeneous group and shows variable outcome. This study aims to determine the prognostic value of routinely assessed variables, singly and in combination, in LN−/ER+/HER2− BC patients.
Journal Title: Histopathology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!